1Department of Biomedicine, University Basel, Basel, Switzerland
2Epinova Discovery Performance Unit, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre, Stevenage, Herts, UK
3Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland
*Address reprint requests to: Department of Biomedicine, University Hospital Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland
E-mail:[email protected]
Received 30 October 2010; accepted January 5, 2011
Grant sponsor: Swiss National Science Foundation; Grant Numbers: 320000_116106, 320030_130243; Grant sponsor: Swiss Cancer League/Oncosuisse; Grant Numbers: OCS-02192-02-2008, KLS-02522-02-2010.
Potential conflict of interest: Nothing to report.
This work was supported by the Swiss National Science Foundation (grants 320000_116106 and 320030_130243) and the Swiss Cancer League/Oncosuisse (grants OCS-02192-02-2008 and KLS-02522-02-2010).
fax: +41 61 265 53 52
Additional Supporting Information may be found in the online version of this article.